The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease.
- collapse Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany
- collapse European study in patients with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis at gastrointestinal risk: A restrospective, non-internventional study of Vimovo™ prescribing patterns.
- collapse Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
- collapse An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
- collapse Open-Label Positron Emission Tomography Study with the Selective β Amyloid Radioligand [18F]AZD4694 to Assess the Effects of Varying Radioligand Mass on Binding Parameters in Healthy Volunteers and Patients with Alzheimer’s Disease
- collapse A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative, Phase 4 Study
- collapse Assessment of MDD management strategies in Andalusia: A Sub-analysis of the PismaEP Study
- collapse Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up
- collapse A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)
